Mobia Medical began trading on Nasdaq after pricing its IPO at $15 per share, raising about $150 million. The company sold 10 million shares at the midpoint of its $14–$16 target range and ended the first day of trading down to $11.75. Mobia’s lead product is Vivistim Paired VNS, a vagus-nerve stimulation therapy intended to improve upper-limb function in chronic ischemic stroke survivors with moderate to severe impairments. The listing offers a new route for stroke-device investors to track clinical evidence and commercial readiness. For biotech and health-tech stakeholders, the debut also reflects continued financing capacity for neuro-rehabilitation modalities with defined patient populations and technology-driven differentiation.